Psychiatry & Neurology Doctors in Payson, UT Accepting Medicare

5 Psychiatry & Neurology doctors found. Showing 1 - 5

Dr. Kevin Lee, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1000 E 100 N, Payson, UT 84651 Phone: 801-465-7041

Brian Eugene Elledge, DO Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 1000 E 100 N, Payson, UT 84651 Phone: 801-465-7041    Fax: 801-465-7409

Dr. Lyle Milton Kinikini, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 97 Professional Way, Payson, UT 84651 Phone: 801-429-8000

Scott David Daniels, MD, MHA Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1000 E 100 N, Payson, UT 84651 Phone: 801-465-7041

Dr. Brian L Harlan, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 1000 E 100 N, Payson, UT 84651 Phone: 801-299-3781

News Archive

Targanta Therapeutics presents preclinical data on Oritavancin against Clostridium difficile infection

Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.

HCSC offers CareProfile tool to assist physicians, healthcare facilities identify health risks

Health Care Service Corporation is offering physicians and healthcare facilities access to a new tool that will assist them in identifying health risks for 9 million patients across the country. The CareProfile® is an electronic health record (EHR) created with the collaborative input of MEDecision, Availity and HCSC's Blue Cross and Blue Shield plans in Illinois, New Mexico, Oklahoma and Texas.

Parents' income and educational level linked to children's physical activity, screen time

Parents' income and educational level are associated with their children's physical activity and screen time, according to a new study from the University of Eastern Finland.

Amylin, Lilly update on FDA review of Byetta (exenatide) injection monotherapy submission

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of Byetta (exenatide) injection as stand-alone therapy (monotherapy) in people with type 2 diabetes who are not achieving acceptable blood sugar control.

FDA's new sunscreen regulations will help reduce skin cancer risk

The American Academy of Dermatology Association (Academy) today said that the U.S. Food and Drug Administration's (FDA) new sunscreen regulations will help Americans reduce their risk for skin cancer by guiding them to the most effective sunscreens and advising them on other sun-protection measures.

Read more Medical News

› Verified 7 days ago